OBJECTIVE: To evaluate the impact of methadone dose on post-release retention in treatment among HIV-infected prisoners initiating methadone maintenance treatment (MMT) within prison. METHODS: Thirty HIV-infected prisoners meeting DSM-IV pre-incarceration criteria for opioid dependence were enrolled in a prison-based, pre-release MMT program in Klang Valley, Malaysia; 3 died before release from prison leaving 27 evaluable participants. Beginning 4 months before release, standardized methadone initiation and dose escalation procedures began with 5mg daily for the first week and 5mg/daily increases weekly until 80 mg/day or craving was satisfied. Participants were followed for 12 months post-release at a MMT clinic within 25 kilometers of the prison. Kaplan-Meier survival analysis was used to evaluate the impact of methadone dose on post-release retention in treatment. FINDINGS: Methadone dose ≥80 mg/day at the time of release was significantly associated with retention in treatment. After 12 months of release, only 21.4% of participants on <80 mg were retained at 12 months compared to 61.5% of those on ≥80 mg (Log Rank χ(2)=(1,26) 7.6, p<0.01). CONCLUSIONS: Higher doses of MMT at time of release are associated with greater retention on MMT after release to the community. Important attention should be given to monitoring and optimizing MMT doses to address cravings and side effects prior to community re-entry from prisons.
OBJECTIVE: To evaluate the impact of methadone dose on post-release retention in treatment among HIV-infected prisoners initiating methadone maintenance treatment (MMT) within prison. METHODS: Thirty HIV-infected prisoners meeting DSM-IV pre-incarceration criteria for opioid dependence were enrolled in a prison-based, pre-release MMT program in Klang Valley, Malaysia; 3 died before release from prison leaving 27 evaluable participants. Beginning 4 months before release, standardized methadone initiation and dose escalation procedures began with 5mg daily for the first week and 5mg/daily increases weekly until 80 mg/day or craving was satisfied. Participants were followed for 12 months post-release at a MMT clinic within 25 kilometers of the prison. Kaplan-Meier survival analysis was used to evaluate the impact of methadone dose on post-release retention in treatment. FINDINGS:Methadone dose ≥80 mg/day at the time of release was significantly associated with retention in treatment. After 12 months of release, only 21.4% of participants on <80 mg were retained at 12 months compared to 61.5% of those on ≥80 mg (Log Rank χ(2)=(1,26) 7.6, p<0.01). CONCLUSIONS: Higher doses of MMT at time of release are associated with greater retention on MMT after release to the community. Important attention should be given to monitoring and optimizing MMT doses to address cravings and side effects prior to community re-entry from prisons.
Authors: Andiea Harris; Daniel Selling; Charles Luther; Jason Hershberger; Joan Brittain; Samuel Dickman; Alvin Glick; Joshua D Lee Journal: Subst Abus Date: 2012 Impact factor: 3.716
Authors: Robert P Schwartz; David A Highfield; Jerome H Jaffe; Joseph V Brady; Carol B Butler; Charles O Rouse; Jason M Callaman; Kevin E O'Grady; Robert J Battjes Journal: Arch Gen Psychiatry Date: 2006-01
Authors: Jacob M Izenberg; Chethan Bachireddy; Jeffrey A Wickersham; Michael Soule; Tetiana Kiriazova; Sergii Dvoriak; Frederick L Altice Journal: Int J Drug Policy Date: 2014-02-28
Authors: Chethan Bachireddy; Michael C Soule; Jacob M Izenberg; Sergey Dvoryak; Konstantin Dumchev; Frederick L Altice Journal: Drug Alcohol Depend Date: 2013-09-27 Impact factor: 4.492
Authors: Roman Shrestha; Michael Copenhaver; Alexander R Bazazi; Tania B Huedo-Medina; Archana Krishnan; Frederick L Altice Journal: AIDS Behav Date: 2017-04
Authors: Alexander R Bazazi; Jeffrey A Wickersham; Martin P Wegman; Gabriel J Culbert; Veena Pillai; Roman Shrestha; Haider Al-Darraji; Michael M Copenhaver; Adeeba Kamarulzaman; Frederick L Altice Journal: Contemp Clin Trials Date: 2017-05-04 Impact factor: 2.226